Dose-dense adjuvant chemotherapy for primary breast cancer by Fornier, Monica & Norton, Larry
64
AC = doxorubicin and cyclophosphamide; CALGB = Cancer and Leukemia Group B; CMF = cyclophosphamide, methotrexate, and 5-fluorouracil;
CSF = colony-stimulating factor; DFS = disease-free survival; EC = epirubicin and cyclophosphamide; ETC = epirubicin, paclitaxel, and cyclophos-
phamide; FAC/FEC = 5-fluorouracil, doxorubicin or epirubicin, and cyclophosphamide; NSABP = National Surgical Adjuvant Breast and Bowel
Project; OS = overall survival.
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Abstract
Adjuvant chemotherapy has been proven to reduce significantly
the risk for relapse and death in women with operable breast
cancer. Nevertheless, the prognosis for patients presenting with
extensive axillary lymph node involvement remains suboptimal. In an
attempt to improve on the efficacy of existing chemotherapy, a
phase III intergroup trial led by the Cancer and Leukemia Group B
(CALGB 97-41) was designed, which tested a mathematical
model of tumor growth based on the Norton–Simon hypothesis.
This hypothesis, developed about 3 decades ago, and the kinetic
model derived from it, created the basis of the concepts of dose
density and sequential therapy, both of which were tested in
CALGB 97-41. This large prospective randomized trial
demonstrated that shortening the time interval between each
chemotherapy cycle while maintaining the same dose size resulted
in significant improvements in disease-free and overall survival in
patients with node-positive breast carcinoma. This finding is highly
relevant and has immediate implications for clinical practice.
Introduction
Breast cancer is the most commonly diagnosed form of
cancer and is the second most common cause of cancer-
related death in women, both in Europe and in the USA. It
was estimated that in the year 2004 about 40,100
patients would die from metastatic breast carcinoma in the
USA [1,2]. Although increased patient awareness and
improved screening techniques (including mammography,
ultrasound, and breast magnetic resonance imaging) now
permit early detection of localized and resectable tumors,
many women still die from recurrent breast carcinoma,
suggesting that a substantial number of patients already
have distant micrometastasis at the time of diagnosis.
With time, a significant number of patients will develop
metastatic disease, even after seemingly curative surgery
and radiotherapy. Systemic adjuvant chemotherapy for
early-stage breast cancer is utilized to eradicate
microscopic deposits of cancer cells that may have
spread or metastasized from the primary breast cancer,
and so it is recommended in large groups of patients to
prevent or delay progression, based on risk assessment.
In the 1990s, the Early Breast Cancer Trialists’
Collaborative Group published overviews, consolidating
data from the randomized trials using meta-analytical
techniques. This methodology has the advantage of being
able to combine data from many small under-powered
trials, consideration of the individual results from which
might have led to negative or positive conclusions [3].
Adjuvant chemotherapy has been proven to reduce
significantly the risk for relapse and death in women with
operable breast cancer, and therapy with anthracycline-
containing regimens has been shown to confer a small but
significant benefit over the classic CMF (cyclophos-
phamide, methotrexate, and 5-fluorouracil) combinations
(Table 1). The most recent Early Breast Cancer Trialists’
Collaborative Group meta-analysis [3] showed reductions
in the annual hazard rate for recurrence and death of
23.5% and 14.3%, respectively. However, the absolute
magnitude of the effect is modest and the risk for relapse
remains significant, especially in patients with metastatic
involvement of axillary lymph nodes.
The Oxford overview [3] confirmed that polychemotherapy
(more than two agents) offers a survival advantage
compared with single agents in the adjuvant setting. Four
to six courses of therapy (3–6 months) appear to confer
optimal benefit, with the administration of additional
courses adding to toxicity without substantially improving
overall benefit.
As previously mentioned, the available data indicate that
adjuvant chemotherapy with an anthracycline-containing
regimen results in a small but statistically significant
improvement in survival compared with regimens that do
not contain an anthracycline. The current standard
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adjuvant anthracycline-containing regimens are as follows:
doxorubicin and cyclophosphamide (AC); epirubicin and
cyclophosphamide (EC); cyclophosphamide, doxorubicin,
and 5-fluorouracil; 5-fluorouracil, doxorubicin or epirubicin,
and cyclophosphamide (FAC/FEC); AC followed by CMF;
doxorubicin or epirubicin followed by CMF; AC followed
by paclitaxel; and docetaxel, doxorubicin, and cyclophos-
phamide. Although CMF is commonly utilized for lower
risk, node-negative breast carcinomas, regimens containing
an anthracycline and/or taxanes are usually recommended
for higher risk, node-positive breast carcinomas. Taxanes,
including paclitaxel and docetaxel, were recently
introduced in the adjuvant setting for breast carcinoma.
Currently available phase III data with adjuvant paclitaxel–
anthracycline combinations demonstrate their significant
superiority in terms of clinical outcome when compared
with doxorubicin-based, non-taxane-containing combina-
tions. The Cancer and Leukemia Group B (CALGB)
93-44 trial reported a significant improvement in disease-
free survival (DFS) at 5 years (70% versus 65%) and
overall survival (OS; 80% versus 77%) for the sequential
addition of paclitaxel to AC [4]. The National Surgical
Adjuvant Breast and Bowel Project (NSABP) trial B28
reported similar results [5]. In the Breast Cancer
International Research Group 001 trial [6] the docetaxel,
doxorubicin, and 5-fluorouracil combination was significantly
superior to FAC.
Dosing and dose escalation
In an attempt to improve the efficacy of chemotherapy in
breast cancer, dose intensification has been evaluated
extensively over the past decade. Dose intensity is
calculated by dividing the total dose of drug given per
surface area by the duration of treatment. It is expressed
as mg/m2 per week [7]. The most widely used method of
increasing dose intensity has been dose escalation. Dose
escalation is tested by comparing higher doses with lower
ones. In some dose ranges escalation improves efficacy,
and in some dose ranges it does not.
The dose escalation concept was based on the Skipper–
Schabel–Wilcox model, also termed the log-kill model –
the first significant proliferation model in clinical oncology
[8]. According to this model, enough cycles of enough
drugs at high enough doses should be able to kill a high
percentage, if not all, of the cells. Unfortunately, this has
not been clinically proven to be true for breast carcinoma.
Dose escalation randomized trials have demonstrated a
threshold effect for the AC combination, with doses of
60 mg/m2 doxorubicin and 600 mg/m2 cyclophosphamide
appearing optimal. Moderate to marked dose escalation of
cyclophosphamide did not prove beneficial in two NSABP
trials, and, disturbingly, there was a report of 21 cases of
myeloproliferative disorders in the NSABP B25 trial
[9,10]. Similar results were suggested for doxorubicin in
the report of the CALGB 93-44 trial [4]. Here, a 50%
increase (60 mg/m2, 75 mg/m2, and 90 mg/m2) in
doxorubicin dose and dose intensity (administered every
21 days) did not improve outcome.
There is currently no convincing evidence demonstrating
that that more dose escalated treatment regimens (e.g.
high-dose chemotherapy with peripheral stem cell
support) result in overall improved outcomes compared
with the administration of polychemotherapy programs at
standard dose levels [11].
Dose density
Tumor cell growth kinetics show that human solid tumors
do not exhibit an exponential growth pattern, but rather are
better fit by a sigmoid growth pattern, for which the
Gompertzian equation is the most commonly used. In the
Gompertzian equation, the doubling time is not constant
but rather increases with increasing tumor size, up to a
certain mass/volume [12].
An alternative model to the Skipper–Schabel–Wilcox one,
the Norton–Simon model, predicts that the best way to
destroy an heterogeneous mix of cancer cells is to
eradicate the numerically dominant, faster growing cells
first, followed by eradication of the more slow growing,
resistant cells [11]. This is termed sequential therapy,
which has been proven to be clinically superior to
alternating therapy. The sequential schedule increases the
intensity of drug exposure, and is predicted to minimize
Table 1
Impact of adjuvant chemotherapy on reducing annual odds of recurrence and death 
Comparison (n) Recurrence Death
CMF versus nil (8150) +24 ± 3 +14 ± 4
CMF+ versus nil (3218) +20 ± 5 +15 ± 5
Anthracyclines+ versus CMF (6950) +12 ± 4 +11 ± 5
Longer versus shorter (6104) +7 ± 4 –1 ± 5
Values are expressed as percentage ± standard deviation. Data from Early Breast Cancer Trialists’ Collaborative Group [3]. CMF,
cyclophosphamide, methotrexate and 5-fluorouracil.66
Breast Cancer Research    Vol 7 No 2 Fornier and Norton
tumor cell regrowth between cycles. The total impact of
therapy could relate to the cell kill for each dose, the
duration of drug administration, and the rate of tumor
growth between each treatment. If so, then a fixed cell kill
achieved at shorter time intervals should improve the
overall impact of therapy. This concept is termed ‘dose
density’ [13]; regrowth of resistant cells during and
between cycles of chemotherapy is theoretically a
principal cause of treatment failure. Suppression of
cancer cell regrowth could be accomplished by
repetitive cycles of chemotherapy. The increased dose
exposure is a consequence of shortened inter-treatment
intervals for each drug or combination and not of
increased doses, and such treatment is therefore called
more ‘dose dense’ (Fig. 1).
The randomized trial of doxorubicin and CMF from the
National Cancer Institute of Milan [14] can be interpreted
as a ‘proof of principle’ of the dose dense hypothesis. In
that study, adjuvant sequential chemotherapy with
doxorubicin for four cycles followed by CMF was
compared with the same regimen delivered in an
alternating manner. Interestingly, the authors expected the
alternating regimen to prove superior, based on the
Goldie–Coldman hypothesis [15]. Instead, the sequential
(more dose dense) plan was associated with significantly
improved DFS and OS. Bonadonna and coworkers [14]
concluded that, although in the alternating plan the four
cycles of doxorubicin were spread over 27 weeks, in the
sequential plan they were administered within 9 weeks,
and therefore the increased dose intensity of doxorubicin
could account for the superiority of the latter plan.
Functionally, the intensity of the treatment was increased
by shortening the intervals without increasing dose levels
of doxorubicin, providing clinical support for exploration of
the hypothesis that more dose dense chemotherapy can
improve outcomes.
Because of the availability of hematopoietic growth factors
to reduce granulocytopenia and risk for infections, the
‘dose dense’ approach could be evaluated in a series of
pilot adjuvant trials at Memorial Sloan-Kettering Cancer
Center [16–18], with promising results. It was subse-
quently tested in a large phase III adjuvant trial in node-
positive breast cancer; the CALGB study 97-41 [19]
compared sequential doxorubicin, paclitaxel, and cyclo-
phosphamide at standard dose levels of 60 mg/m2,
175 mg/m2, and 600 mg/m2, respectively, against
concurrent AC, followed by paclitaxel, at the same dose
levels. A separate randomization in this trial compared
every 2 weeks with every 3 weeks dosing to assess the
relative efficacy and toxicity of more or less dose dense
therapy (Fig. 2). The every 2 weeks schedule was
delivered with granulocyte colony-stimulating factor (CSF)
support. This trial is particularly informative because it was
a pure test of the dose density concept; all patients
received the same drugs, the same number of drug cycles,
at the same cumulative dose and the same individual
doses, in all arms of the trial. A total of 2005 patients were
randomized, all with node-positive resected breast
carcinoma.
In that study, the incidence of grade IV neutropenia and
treatment delays due to hematologic toxicity was
significantly reduced and the efficacy was increased with
the every 2 weeks schedule as compared with the every
3 weeks schedule. All four treatment schedules were
proven to be feasible and safe. However, at a median
follow up of 36 months DFS and OS were both
statistically superior for the every 2 weeks, dose dense
arm (3-year DFS: 85% versus 81%, P = 0.01; 3-year OS:
92% versus 90%, P = 0.013), regardless of predictive
factors such as the number of positive nodes, tumor size,
menopausal status, and tumor estrogen receptor status,
Figure 1
More frequent dosing can prevent cancer cell regrowth.
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Figure 2
Cancer and Leukemia Group B (CALGB) 97-41 node-positive trial:
2 × 2 factorial design. G-CSF, granulocyte colony-stimulating factor.
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thus translating increased dose density into increased
clinical benefit (Figs 3 and 4). There was no difference in
DFS or OS between the sequential and the concurrent
arms. As mentioned above, the DFS and OS advantages
of dose density were not accompanied by an increase in
toxicity. Indeed, the use of filgrastim in the every 2 weeks,
dose dense regimens resulted in a statistically significant
decrease in granulocyte toxicity. Furthermore, the study
utilized a baseline granulocyte count of 1000/µl (rather
than the traditional 1500/µl) for administering chemo-
therapy, and this was proven to be safe. CALGB 97-41
showed not only the feasibility of this approach, but also
the superiority of dose dense over conventional chemo-
therapy. These findings are exciting and are consistent
with previous mathematical model predictions that
shortening the interval between chemotherapy cycles
could result in more effective eradication of malignant
cells, potentially improving survival.
Evidence from other trials
Other trials have tested the dose dense hypothesis, with
positive results; however, not all of them are ‘clean’ tests
of the dose density concept. In fact, the interpretability of
studies may often be confounded by the design, in that
the two arms are not equal in terms of the number of
cycles or total drug dose, or even different drugs are
delivered [20].
Möbus and colleagues [21] from the Arbeitsgemeinschaft
für Gynaekologische Onkologie group recently demon-
strated the superiority of adjuvant dose dense epirubicin,
paclitaxel, and cyclophosphamide (ETC), every 2 weeks
with filgrastim support, over sequential EC followed by
paclitaxel every 3 weeks (Fig. 5). The authors defined this
trial as a comparison of both dose dense and dose
intense chemotherapy versus standard chemotherapy: in
fact, the experimental ETC arm had higher cumulative
doses of chemotherapy than did the 3-weekly arm. The
study revealed a benefit in terms of DFS and OS for the
ETC arm, although, given the higher doses delivered, it is
not clear whether the superiority was purely conveyed by
dose density alone.
Venturini and coworkers [22], from the Gruppo
Oncologico del Nord-Ovest group, recently reported on
the comparative efficacy of adjuvant standard versus
accelerated FEC for patients with early breast carcinoma.
That trial was similar to CALGB 97-41 in that it was
designed in a manner that provided a pure test of the
‘dose dense’ concept; patients were randomly assigned to
receive six cycles of FEC (fluorouracil 600 mg/m2,
epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2)
given either every 3 weeks (FEC21) or every 2 weeks
(FEC14) with CSF support (Fig. 6). All patients received
the same number of cycles, the same drugs, and the same
drug levels. After a median follow-up period of 6.7 years,
there was a statistically nonsignificant reduction in the risk
for death in the FEC14 arm (hazard ratio 0.82, 95%
confidence interval 0.6–1.12; P = 0.22). The hazard ratio
was in the same direction as that of CALGB 97-41, but it
did not reach statistical significance.
There were, however, several important differences
between the Venturini and CALGB 97-41 trials, including
the sample size (1214 versus 2005 patients, respectively),
selection criteria (34% of patients in the Venturini trial had
node-negative disease), and the chemotherapy regimens
utilized. The Venturini trial was also relatively under-
Available online http://breast-cancer-research.com/content/7/2/64
Figure 3
Disease-free survival by density. Adapted from Citron and coworkers [19].
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Figure 4
Overall survival by density. Adapted from Citron and coworkers [19].
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powered. Furthermore, it is preferable to use the
sequential AC followed by paclitaxel therapy, as used in
the CALGB 97-41 study, rather than FEC14, as utilized in
the Venturini trial. In fact, previous studies have
demonstrated that the FEC100 regimen (containing
100 mg/m2 epirubicin) is more effective than FEC50
(containing 50 mg/m2 epirubicin) when given every
3 weeks in early-stage breast cancer [23]. The
assumption could be made that the use of the FEC100
regimen given every 2 weeks with granulocyte CSF may
provide benefit. However, in a pilot trial [24] we recently
reported that FEC100 regimen delivered every 2 weeks
was not feasible because of nonhematologic toxicity,
suggesting that caution should be exercised in adopting
this approach for different regimens.
Future avenues
We await the results of multiple ongoing trials currently
testing the concept of dose density. The Eastern
Cooperative Group adjuvant trial 11-99 is a large 4-arm,
phase III trial with 4 arms: patients were treated with 3-
weekly AC × 4 cycles followed by either 3-weekly
paclitaxel × 4 cycles, or weekly paclitaxel × 12 cycles, or
3-weekly docetaxel × 4 cycles, or weekly docetaxel × 12
cycles That study completed accrual in January 2002 and
will answer the question regarding whether dose dense
weekly taxane is superior to conventionally administered
taxane (and which one). The National Cancer Institute of
Canada MA.21 trial is currently comparing three regimens:
standard AC for four cycles followed by paclitaxel for four
cycles every 3 weeks; cyclophosphamide, epirubicin, and
5-fluorouracil for six cycles; and biweekly EC for six cycles
followed by paclitaxel for four cycles every 3 weeks.
Interestingly, in the latter regimen only EC is dose dense,
and results will reveal whether there is any therapeutic
benefit in accelerating part of a regimen. At Memorial
Sloan Kettering Cancer Center, we are currently exploring
the feasibility of EC and paclitaxel at 10–11 days (denser)
intervals, with filgrastim support, in an attempt to take the
concept of dose density to a further degree (Fig. 7).
Conclusion
Breast cancer remains a worldwide public health concern,
despite the fact that mortality rates have been declining in
the USA, Canada, and Europe [25] Advances in detection,
diagnosis, and treatment of breast cancer have certainly
contributed to this decline, but the search for optimal
regimens and their applications is still ongoing. Results
with dose-dense chemotherapy in CALGB 97-41 are
exciting, showing improved DFS and OS and less grade 4
neutropenia. The findings of that study suggest that dose
dense scheduling with appropriate chemotherapy
regimens and CSF support is ‘ready for prime time’ and
can replace conventional dosing as the new standard of
care in primary breast cancer. On the basis of current data,
practicing oncologists should consider treating patients
with breast cancer in this dose dense manner. However,
extrapolating these data to all regimens outside a clinical
trial setting should be done with caution, because
unexpected toxicities may emerge. These findings suggest
important avenues for future research in both breast cancer
and other chemosensitive tumors, and confirmatory studies
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Figure 5
Phase III, prospective, randomized, multicenter Arbeitsgemeinschaft für
Gynaekologische Onkologie group trial. Adapted from Möbus and
coworkers [21].
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Figure 6
Phase III adjuvant trial comparing standard versus accelerated
5-fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen in
early breast cancer patients. Results from the Gruppo Oncologico del
Nord-Ovest group MIG1 study. G-CSF, granulocyte colony-stimulating
factor. Adapted from Venturini and coworkers [22].
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Figure 7
Memorial Sloan-Kettering Cancer Center Pilot trial of epirubicin and
cyclophosphamide followed by paclitaxel at 10–11 day intervals. G-
CSF, granulocyte colony-stimulating factor.
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are encouraged; in this regard, it is of paramount
importance to continue to support clinical trials.
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